ABSTRACT -Background -Hepatitis C virus (HCV) infection is a serious public health problem, that affects approximately 170 million people worldwide.
INTRODUCTION
Hepatitis C virus (HCV) infection is a serious public health problem, that affects approximately 170 million people worldwide (1) . It continues to be the leading cause of death from liver disease and, despite recent medical advances in HCV therapy, it is the principal indication for liver transplantation in the United States (2, 3) . Eightyfive percent of the infected people fail to achieve clearance of the virus and become chronically infected (4) . Approximately 20% may develop hepatic cirrhosis within 20 years, characterized by progressive replacement of the functional hepatic architecture by non-functional fibrotic tissue. Each year, 6% of cirrhotic patients are expected develop terminal hepatic disease, and 4% to develop hepatocellular carcinoma (HCC) (5, 6) . Chronic HCV infection is associated with hepatic insulin resistance (IR) and an increased risk of diabetes in HCV-infected patients has been well described (7) . This large prevalence of type 2 diabetes (T2DM) in HCV remains even when cirrhotic patients are excluded from the analysis (8) (9) (10) , indicating that cirrhosis could be diabetogenic by itself (11) . Although insulin resistance (IR) has also been detected also in subjects with minimal or no fibrosis, an increase of homeostatic model assessment of insulin resistance (HOMA-IR) has been associated with the presence of more advanced fibrosis (12) . Other studies confirmed these findings and showed a correlation between the degree of fibrosis and IR (13, 14) . T2DM and IR were observed to be independent predictors of liverrelated mortality (15, 16) , moreover IR was associated with fibrosis progression and the stage of fibrosis (12) . In patients receiving interferon (IFN)-based therapy, RomeroGomez et al. (17) showed that IR was associated with lower sustained virological response (SVR) rates, independent of a viral genotype. Baseline IR did not affect the outcomes of direct acting antiviral (DAA) -based therapy and HOMA-IR scores had no effect on virological response to interferon free therapy (18, 19) .
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METHODS
In this prospective study, we assessed patients treated with interferon free therapy from 2015 to 2017. The study was conducted at the Viral Hepatitis Outpatient Clinic of Botucatu Medical School and was approved by the Committee on Ethics in Research of the Botucatu Medical School. The data were collected at the beginning of treatment (baseline: t-base) and in the twelfth week after treatment was completed (t-SVR12).
The inclusion criteria were: presence of chronic hepatitis C infection (presence of RNA-HCV); age ≥18 years; completion of DAAs' therapy; presence of diabetes with intake of oral hypoglycemic agents, and samples collected during the study period. The exclusion criteria were as follows: HBV and/or HIV co-infection; hepatocellular carcinoma at baseline; diabetic patients taking insulin and transplanted patients (liver and kidney).
Fibrosis was assessed by hepatic elastography or biopsy (METAVIR classification) (21) . Cirrhosis was determined clinically or by imaging examination. HOMA-IR was calculated as fasting insulin (μU/mL) × fasting glucose (mmol/L)/22.5) (22) . To determine the delta HOMA-IR value, the difference was calculated as the HOMA-IR at t-base -HOMA-IR at t-SVR12.
Descriptive statistical analyses were performed to establish a comparison of the delta HOMA-IR between the groups: the general study population (all patients, including diabetics patients) and the special population (We excluded patients with normal values of HOMA-IR, which is <2.5, and with diabetes). For delta HOMA-IR, delta insulin and delta glucose, the paired t test was performed. A generalized linear model assuming log-binding function was performed for delta HOMA-IR evaluated by fibrosis. A P-value of <0.05 was considered significant.
RESULTS
Of the 274 consecutive patients, 150 were included, and 75 were cirrhotic. Six patients died during the treatment period,15 were excluded for taking insulin, 10 did not achieve SVR, 3 had a hepatic nodule at baseline, 7 underwent kidney or liver transplantation and 83 did not have data for HOMA-IR in all the periods indicated.
The mean age was 55.3±9.97 and body mass index (BMI) was 27.4±5.18. Twenty-two (14.67%) were diabetic patients who required oral hypoglycemic agents, and 17 (11%) were cirrhotic (P=0.01).
In TABLE 1 the baseline results of the general study population are provided. Mean glucose and HOMA-IR increased at t-SVR12 (102.36±24.52 and 3.72±3.26 respectively), but insulin decreased (14.03±10.32).
In TABLE 2 the changes in of delta glucose, delta insulin and delta HOMA-IR values are provided.
Altough the delta HOMA-IR was negative at t-SVR12, there was no statistical difference. When we evaluated the delta HOMA-IR based on the presence of advanced fibrosis or not, no statistical difference was found either. (P=0.58).
Analyses of special population -when we excluded patients with normal values of HOMA-IR, which is <2.5 and with diabetes.
Excluding diabetic patients and those who had normal HOMA-IR values (HOMA-IR <2.5) there were 75 patients in total, 21 (28%) were F≤2, 12 (16%) were F3 and 42 (56%) were F4 (TABLE3).
In this population, the mean glucose, insulin and HOMA-IR values decreased at t-SVR12 (98.25±14.58, 16.56±7.64, 4.09±2.13), respectively. In TABLE 4 delta glucose, delta insulin and delta HOMA-IR are provided after excluding diabetic patients and those who had normal values of HOMA-IR (<2.5). The Delta HOMA-IR decreased significantly at t-SVR12. When categorized by fibrosis, there was no statistical difference (P=0.98).
DISCUSSION
Numerous studies suggest that HCV can harm insulin signaling and increase the onset of T2DM (23, 24) . In HCV-infected patients the reported prevalence of IR has increased from 30% to 70%, irrespective of the severity of hepatic disease, and is genotype-specific (2, 13) . In our study, the incidence of T2DM was 14.6%, and 11% of patients were cirrhotic and 3.33% were non cirrhotic (P<0.01).
Diabetes mellitus caused by cirrhosis is called hepatogenous diabetes. This type of diabetes is most likely caused by IR with a lower hepatic extraction of insulin or by some dysfunction of pancreatic beta cells; however, this mechanism is not completely understood (25) . Classification of patients according to hepatogenous diabetes or hereditary T2DM to better determine the effect of HCV eradication in these conditions, would be beneficial (26) . However, this is not always possible because there is no standard definition of hepatogenous diabetes, even in international guidelines.
The impact of IR on the treatment efficacy of DAAs has greatly reduced because of the recent development of high potency antivirals (16) .However, post-treatment outcomes with respect to glucose abnormalities have rarely been investigated. Thus, the correlation and/or changes of IR with treatment efficacy of DAAs in a realworld scenario needs more assessment.
Our data showed that the delta HOMA-IR increased at SVR12, but the result was not statistically significant, when the general study population, including diabetic patients, were studied. Additionally, there was no association between HOMA-IR and low and high levels of fibrosis. In this population, there was a slight increase of glucose and HOMA-IR, while the insulin levels decreased. A study by Jeef-Fu Huang et al. (19) , that included 65 native Tawainese patients with chronic hepatitis C treated with DAAs assessing HOMA-IR, it was observed that, the levels of HOMA-IR decreased at SVR12, compared to baseline, even though there was no statistical difference. In addition, the mean glucose levels decreased in diabetic patients at SVR12. The study did not show the level of fibrosis in the patients. Another study that consisted of 110 patients with chronic hepatitis C, advanced fibrosis and T2DM that analyzed the impact of SVR on fasting glucose and glycated hemoglobin, also showed a significant reduction in fasting glucose, as SVR12 was the only factor associated with this improvement (27) . However, they did not evaluate HOMA-IR.
There is no consensus regarding the cut-off value for diagnosing IR (28, 29) . Some studies use a HOMA-IR value between 1.5 and 3.0 to determine insulin resistance (17, (30) (31) (32) . In our study, we used HOMA-IR >2.5 for the diagnosis of insulin resistance. In Brazil, there was a populational study of non-diabetic patients without HCV infection from the Brazilian Study of Metabolic Syndrome (32) .In this study the optimal diagnostic level of HOMA-IR was between 2.3 and 2.7, which is close to the level used in our study.
In our study, on excluding diabetic patients and those with a HOMA-IR <2.5 (special population), a decrease in glucose, insulin and HOMA-IR values at t-SVR12 was observed. A study of 133 HCV genotype 1 patients with advanced liver fibrosis without T2DM (33) that evaluated the impact of HCV clearance by anti-viral treatments on IR and glycemic control, showed similar results to ours. Glucose, insulin and HOMA-IR values decreased at the end of treatment, resulting in values that remained constant after SVR12. The HOMA-IR values were associated with advanced liver fibrosis, however in our study, we did not find a significant association between the delta HOMA-IR and fibrosis stage. This might be attributable to the small study population of 75 patients after excluding diabetic patients and those with HOMA-IR <2.5.
CONCLUSION
Glucose and HOMA-IR increased at t-SVR12, but insulin decreased in the general population. The delta HOMA-IR increased, but there was no association with the stage of fibrosis. Excluding diabetic patients and those who had normal values of HOMA-IR, glucose, insulin, HOMA-IR and delta HOMA-IR decreased at t-SVR12. In addition, no association with fibrosis was found. 
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